{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:43:29Z","timestamp":1793447009126,"version":"4.5.0"},"reference-count":246,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder with substantial socioeconomic impact, characterized by the gradual loss of dopaminergic neurons, dopamine deficiency, and pathological processes such as neuroinflammation, oxidative stress, and \u03b1-synuclein aggregation. Monoamine oxidases (MAOs) are enzymes responsible for the degradation of neuroactive amines, including dopamine, a neurotransmitter essential for motor, cognitive, and behavioral functions. Among these, MAO-B plays a central role in dopamine metabolism, producing reactive metabolites and oxidative species that contribute to the oxidative stress associated with PD pathophysiology. In this context, MAO-B inhibition has emerged as a promising therapeutic strategy. However, specific limitations, such as motor complications linked to prolonged levodopa use and the adverse effects of currently available MAO inhibitors, remain significant clinical challenges. Methods: A comprehensive literature search was conducted using PubMed and SciFinder databases. Keywords such as \u201cMAO inhibitors\u201d, \u201cParkinson\u2019s pathology,\u201d and \u201cParkinson\u2019s disease\u201d were combined with Boolean operators (AND, OR, NOT). The search covered publications from 2010 to 2025. Results: While previous reviews, particularly those by the groups of Guglielmi and Alborghetti, mainly emphasized the clinical use of MAO-B inhibitors and advances in patents, the present review identified approximately 300 compounds synthesized and evaluated as MAO inhibitors, encompassing diverse chemical classes. Among them, selective MAO-B inhibitors exhibited the greatest pharmacological potential, reinforcing the relevance of this isoform as a strategic target in PD therapy. Conclusion: These findings highlight the advances of Medicinal Chemistry in the development of novel MAO-B inhibitors, both as monotherapies for early-stage PD and as adjuvants to levodopa in advanced disease. Collectively, they emphasize the promise of MAO-B inhibitors as candidates for more effective therapeutic interventions in Parkinson\u2019s disease.<\/jats:p>","DOI":"10.3390\/ph18101526","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:10:31Z","timestamp":1760343031000},"page":"1526","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson\u2019s Disease: An Update"],"prefix":"10.3390","volume":"18","author":[{"given":"Luana Vergueiro","family":"Ribeiro","sequence":"first","affiliation":[{"name":"PeQuiM\u2014Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, Alfenas 37133-840, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Emika","family":"Massuda","sequence":"additional","affiliation":[{"name":"PeQuiM\u2014Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, Alfenas 37133-840, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-818X","authenticated-orcid":false,"given":"Vanessa Silva","family":"Gontijo","sequence":"additional","affiliation":[{"name":"PeQuiM\u2014Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, Alfenas 37133-840, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-992X","authenticated-orcid":false,"suffix":"Jr.","given":"Claudio","family":"Viegas","sequence":"additional","affiliation":[{"name":"PeQuiM\u2014Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, Alfenas 37133-840, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological Treatment of Parkinson Disease: A Review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_2","first-page":"88","article-title":"Parkinson\u2019s Disease Genetics and Pathophysiology","volume":"44","author":"Zoghbi","year":"2021","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41531-021-00156-z","article-title":"Meta-Analysis of the Parkinson\u2019s Disease Gut Microbiome Suggests Alterations Linked to Intestinal Inflammation","volume":"7","author":"Romano","year":"2021","journal-title":"NPJ Park. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for Prevalence of Parkinson\u2019s Disease and Its Driving Factors in 195 Countries and Territories to 2050: Modelling Study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wallin, J., and Svenningsson, P. (2021). Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson\u2019s Disease. Int J Mol Sci, 22.","DOI":"10.3390\/ijms22115606"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MJT.0b013e31825b9eb5","article-title":"Monoamine Oxidase Inhibitors and Neuroprotection: A Review","volume":"19","author":"MacKenzie","year":"2012","journal-title":"Am. J. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fnmol.2019.00143","article-title":"Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis","volume":"12","author":"Yeung","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brainresbull.2016.12.004","article-title":"Parkin and PINK1 Functions in Oxidative Stress and Neurodegeneration","volume":"133","author":"Barodia","year":"2017","journal-title":"Brain Res. Bull."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1570159X16666180830100754","article-title":"Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson\u2019s Disease: From Bench to Bedside","volume":"17","author":"Alborghetti","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/13543776.2022.2083501","article-title":"An Updated Patent Review on Monoamine Oxidase (MAO) Inhibitors","volume":"32","author":"Guglielmi","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","article-title":"Neuropathology of Parkinson Disease","volume":"46","author":"Dickson","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2174\/1389557519666191104110908","article-title":"Parkinson\u2019s Disease: A Review from Pathophysiology to Treatment","volume":"20","author":"Marino","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s12264-018-0245-3","article-title":"Dopamine in Parkinson\u2019s Disease: Precise Supplementation with Motor Planning","volume":"34","author":"Chen","year":"2018","journal-title":"Neurosci. Bull."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson Disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hindeya Gebreyesus, H., and Gebrehiwot Gebremichael, T. (2020). The Potential Role of Astrocytes in Parkinson\u2019s Disease (PD). Med. Sci., 8.","DOI":"10.3390\/medsci8010007"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.mehy.2017.05.022","article-title":"Parkinson\u2019s Disease; the Hibernating Spore Hypothesis","volume":"104","author":"Berstad","year":"2017","journal-title":"Med. Hypotheses"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acschemneuro.8b00454","article-title":"Impact of Dopamine Oxidation on Dopaminergic Neurodegeneration","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sarkar, S., Raymick, J., and Imam, S. (2016). Neuroprotective and Therapeutic Strategies Against Parkinson\u2019s Disease: Recent Perspectives. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060904"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s12031-020-01776-5","article-title":"Tau in the Pathophysiology of Parkinson\u2019s Disease","volume":"71","author":"Pan","year":"2021","journal-title":"J. Mol. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","article-title":"\u03b1-Synuclein Oligomers Interact with ATP Synthase and Open the Permeability Transition Pore in Parkinson\u2019s Disease","volume":"9","author":"Ludtmann","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_21","first-page":"1255","article-title":"Dopamine Oxidation Mediates Mitochondrial and Lysosomal Dysfunction in Parkinson\u2019s Disease","volume":"357","author":"Burbulla","year":"2017","journal-title":"Science (1979)"},{"key":"ref_22","first-page":"716871","article-title":"Mitochondrial Dysfunction in Parkinson\u2019s Disease","volume":"2011","author":"Keane","year":"2011","journal-title":"Park. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1007\/s12035-021-02375-0","article-title":"Gut Microbial Metabolites in Parkinson\u2019s Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment","volume":"58","author":"Liang","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s12276-021-00646-3","article-title":"Redefining Differential Roles of MAO-A in Dopamine Degradation and MAO-B in Tonic GABA Synthesis","volume":"53","author":"Cho","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1080\/07391102.2021.1940286","article-title":"In-Silico Evaluations of the Isolated Phytosterols from Polygonum Hydropiper L. Against BACE1 and MAO Drug Targets","volume":"40","author":"Ayaz","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00702-014-1362-4","article-title":"Modulation of Monoamine Oxidase (MAO) Expression in Neuropsychiatric Disorders: Genetic and Environmental Factors Involved in Type A MAO Expression","volume":"123","author":"Naoi","year":"2016","journal-title":"J. Neural Transm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmech.2018.01.003","article-title":"Privileged Scaffolds as MAO Inhibitors: Retrospect and Prospects","volume":"145","author":"Tripathi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-981-10-7757-9_5","article-title":"Monoamine Oxidases","volume":"87","author":"Edmondson","year":"2018","journal-title":"Subcell. Biochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.26452\/ijrps.v12i1.4092","article-title":"Role of Enzymes in Causing Neurological Disorders","volume":"12","author":"Visweswaran","year":"2021","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2174\/1568026611212200007","article-title":"Monoamine Oxidases: The Biochemistry of the Proteins as Targets in Medicinal Chemistry and Drug Discovery","volume":"12","author":"Ramsay","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"McHugh, P.C., and Buckley, D.A. (2015). The Structure and Function of the Dopamine Transporter and Its Role in CNS Diseases, Elsevier. [1st ed.].","DOI":"10.1016\/bs.vh.2014.12.009"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acschemneuro.8b00276","article-title":"Dopamine Oxidation Products as Mitochondrial Endotoxins, a Potential Molecular Mechanism for Preferential Neurodegeneration in Parkinson\u2019s Disease","volume":"9","author":"Biosa","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1586\/14737175.2014.920235","article-title":"Monoamine Oxidase and \u03b1-Synuclein as Targets in Parkinson\u2019s Disease Therapy","volume":"14","author":"Follmer","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26978","DOI":"10.1074\/jbc.M111.249532","article-title":"Oxidation of 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopaminergic Metabolite, to a Semiquinone Radical and an Ortho-Quinone","volume":"286","author":"Anderson","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_35","first-page":"477","article-title":"Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson\u2019s Disease: Past, Present, and Future","volume":"12","author":"Tan","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00401-024-02712-2","article-title":"Characterization of Monoamine Oxidase-B (MAO-B) as a Biomarker of Reactive Astrogliosis in Alzheimer\u2019s Disease and Related Dementias","volume":"147","author":"Healey","year":"2024","journal-title":"Acta Neuropathol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Naoi, M., Maruyama, W., and Shamoto-Nagai, M. (2022). Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911059"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s Disease: Etiopathogenesis and Treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101790","DOI":"10.1016\/j.jddst.2020.101790","article-title":"Parkinson\u2019s Disease: Current Drug Therapy and Unraveling the Prospects of Nanoparticles","volume":"58","author":"Paul","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/bs.irn.2017.01.002","article-title":"Treatment Strategies in Early Parkinson\u2019s Disease","volume":"Volume 132","author":"Marsili","year":"2017","journal-title":"International Review of Neurobiology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/NDT.S54423","article-title":"Amantadine and Cognitive Flexibility: Decision Making in Parkinson\u2019s Patients with Severe Pathological Gambling and Other Impulse Control Disorders","volume":"10","author":"Cera","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_42","first-page":"37","article-title":"Side Effects of a Dopamine Agonist Therapy for Parkinson\u2019s Disease: A Mini-Review of Clinical Pharmacology","volume":"89","author":"Borovac","year":"2016","journal-title":"Yale J. Biol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00702-018-1952-7","article-title":"Inhibitors of MAO-B and COMT: Their Effects on Brain Dopamine Levels and Uses in Parkinson\u2019s Disease","volume":"126","author":"Finberg","year":"2019","journal-title":"J. Neural Transm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-801022-8.00008-8","article-title":"Effects of the Adenosine A2A Receptor Antagonist on Cognitive Dysfunction in Parkinson\u2019s Disease","volume":"Volume 119","author":"Uchida","year":"2014","journal-title":"International Review of Neurobiology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1039\/C8MD00446C","article-title":"Discovery of Monoamine Oxidase Inhibitors by Medicinal Chemistry Approaches","volume":"10","author":"Hong","year":"2019","journal-title":"MedChemComm"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11596310-000000000-00000","article-title":"Monoamine Oxidase B Inhibitors for the Treatment of Parkinson\u2019s Disease A Review of Symptomatic and Potential Disease-Modifying Effects","volume":"25","author":"Schapira","year":"2011","journal-title":"CNS Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105233","DOI":"10.1016\/j.bioorg.2021.105233","article-title":"Discovery of Novel and Potent Safinamide-Based Derivatives as Highly Selective HMAO-B Inhibitors for Treatment of Parkinson\u2019s Disease (PD): Design, Synthesis, In Vitro, In Vivo and In Silico Biological Studies","volume":"115","author":"Elkamhawy","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Elkamhawy, A., Woo, J., Gouda, N.A., Kim, J., Nada, H., Roh, E.J., Park, K.D., Cho, J., and Lee, K. (2021). Melatonin Analogues Potently Inhibit Mao-b and Protect Pc12 Cells Against Oxidative Stress. Antioxidants, 10.","DOI":"10.3390\/antiox10101604"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Duarte, P., Michalska, P., Crisman, E., Cuadrado, A., and Le\u00f3n, R. (2022). Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson\u2019s Disease. Antioxidants, 11.","DOI":"10.3390\/antiox11020247"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1021\/acs.jmedchem.4c02659","article-title":"Network-Based Drug Optimization Toward the Treatment of Parkinson\u2019s Disease: NRF2, MAO-B, Oxidative Stress, and Chronic Neuroinflammation","volume":"68","author":"Duarte","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"105352","DOI":"10.1016\/j.bioorg.2021.105352","article-title":"Discovery of 3,4-Dichloro-N-(1H-Indol-5-Yl)Benzamide: A Highly Potent, Selective, and Competitive HMAO-B Inhibitor with High BBB Permeability Profile and Neuroprotective Action","volume":"116","author":"Elkamhawy","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Elsherbeny, M.H., Kim, J., Gouda, N.A., Gotina, L., Cho, J., Pae, A.N., Lee, K., Park, K.D., Elkamhawy, A., and Roh, E.J. (2021). Highly Potent, Selective, and Competitive Indole-Based MAO-B Inhibitors Protect PC12 Cells against 6-Hydroxydopamine-and Rotenone-Induced Oxidative Stress. Antioxidants, 10.","DOI":"10.3390\/antiox10101641"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.bmcl.2016.03.060","article-title":"An Evaluation of Synthetic Indole Derivatives as Inhibitors of Monoamine Oxidase","volume":"26","author":"Chirkova","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2174\/1871520620999200818160350","article-title":"Indazole as a Privileged Scaffold: The Derivatives and Their Therapeutic Applications","volume":"21","author":"Qin","year":"2020","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/jm500729a","article-title":"Indazole-and Indole-5-Carboxamides: Selective and Reversible Monoamine Oxidase B Inhibitors with Subnanomolar Potency","volume":"57","author":"Tzvetkov","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ejmech.2017.01.011","article-title":"Crystal Structures, Binding Interactions, and ADME Evaluation of Brain Penetrant N-Substituted Indazole-5-Carboxamides as Subnanomolar, Selective Monoamine Oxidase B and Dual MAO-A\/B Inhibitors","volume":"127","author":"Tzvetkov","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ejmech.2018.11.009","article-title":"(Pyrrolo-Pyridin-5-Yl)Benzamides: BBB Permeable Monoamine Oxidase B Inhibitors with Neuroprotective Effect on Cortical Neurons","volume":"162","author":"Tzvetkov","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1080\/14756366.2020.1800666","article-title":"Discovery of N-(1-(3-Fluorobenzoyl)-1H-Indol-5-Yl)Pyrazine-2-Carboxamide: A Novel, Selective, and Competitive Indole-Based Lead Inhibitor for Human Monoamine Oxidase B","volume":"35","author":"Elkamhawy","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bmcl.2015.01.061","article-title":"Inhibition of Monoamine Oxidase by Indole-5,6-Dicarbonitrile Derivatives","volume":"25","author":"Chirkova","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ddr.21425","article-title":"An Investigation of the Monoamine Oxidase Inhibition Properties of Pyrrolo [3,4-f]Indole-5,7-Dione and Indole-5,6-Dicarbonitrile Derivatives","volume":"79","author":"Chirkova","year":"2018","journal-title":"Drug Dev. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ddr.21576","article-title":"Optimization of Pyrrolo[3,4-f]Indole-5,7-Dione and Indole-5,6-Dicarbonitrile Derivatives as Inhibitors of Monoamine Oxidase","volume":"80","author":"Chirkova","year":"2019","journal-title":"Drug Dev. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/acschemneuro.7b00050","article-title":"Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO- B Inhibitors for Treatment of Parkinson\u2019 s Disease","volume":"8","author":"Nam","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"112911","DOI":"10.1016\/j.ejmech.2020.112911","article-title":"Pyrimido[1,2-b]Indazole Derivatives: Selective Inhibitors of Human Monoamine Oxidase B with Neuroprotective Activity","volume":"209","author":"Jismy","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Can, N.\u00d6., Osmaniye, D., Levent, S., Sa\u011flik, B.N., Inci, B., Lg\u0131n, S., \u00d6zkay, Y., and Kaplanc\u0131kl\u0131, Z.A. (2017). Synthesis of New Hydrazone Derivatives for MAO Enzymes Inhibitory Activity. Molecules, 22.","DOI":"10.3390\/molecules22081381"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1016\/j.bmcl.2014.06.015","article-title":"Synthesis of Some Novel Hydrazone and 2-Pyrazoline Derivatives: Monoamine Oxidase Inhibitory Activities and Docking Studies","volume":"24","author":"Ertan","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Turan-zitouni, G., Hussein, W., Sagl\u0131k, B.N., Tabbi, A., and Korkut, B. (2018). Design, Synthesis and Biological Evaluation of Novel N-Pyridyl-Hydrazone Derivatives as Potential Monoamine Oxidase (MAO) Inhibitors. Molecules, 23.","DOI":"10.3390\/molecules23010113"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00702-013-0968-2","article-title":"Synthesis, Molecular Modeling, and In Vitro Screening of Monoamine Oxidase Inhibitory Activities of Some Novel Hydrazone Derivatives","volume":"120","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/jm060869d","article-title":"Selective Inhibitory Activity against MAO and Molecular Modeling Studies of 2-Thiazolylhydrazone Derivatives","volume":"50","author":"Chimenti","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejmech.2011.12.027","article-title":"Synthesis and Biological Assessment of Novel 2-Thiazolylhydrazones and Computational Analysis of Their Recognition by Monoamine Oxidase B","volume":"48","author":"Distinto","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/cmdc.201600202","article-title":"Design, Synthesis, and Evaluation of 2-Amino-6-Nitrobenzothiazole-Derived Hydrazones as MAO Inhibitors: Role of the Methylene Spacer Group","volume":"11","author":"Tripathi","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejmech.2017.03.009","article-title":"MAO Enzymes Inhibitory Activity of New Benzimidazole Derivatives Including Hydrazone and Propargyl Side Chains","volume":"131","author":"Can","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14756366.2019.1571272","article-title":"4-(3-Nitrophenyl)Thiazol-2-Ylhydrazone Derivatives as Antioxidants and Selective HMAO-B Inhibitors: Synthesis, Biological Activity and Computational Analysis","volume":"34","author":"Secci","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2013.05.032","article-title":"Exploring 4-Substituted-2-Thiazolylhydrazones from 2-, 3-, and 4-Acetylpyridine as Selective and Reversible HMAO-B Inhibitors","volume":"66","author":"Chimenti","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ardp.201200318","article-title":"Synthesis and Selective Human Monoamine Oxidase B Inhibition of Heterocyclic Hybrids Based on Hydrazine and Thiazole Scaffolds","volume":"346","author":"Carradori","year":"2013","journal-title":"Arch. Pharm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41598-024-51728-x","article-title":"Isatin-Tethered Halogen-Containing Acylhydrazone Derivatives as Monoamine Oxidase Inhibitor with Neuroprotective Effect","volume":"14","author":"Kumar","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Georgieva, M., Mateev, E., Valkova, I., Kuteva, H., Tzankova, D., Stefanova, D., Yordanov, Y., Lybomirova, K., Zlatkov, A., and Tzankova, V. (2024). Neurotoxicity, Neuroprotection, In Vitro MAOA\/MAOB Inhibitory Activity Assessment, Molecular Docking, and Permeability Assay Studies of Newly Synthesized Hydrazones Containing a Pyrrole Ring. Molecules, 29.","DOI":"10.3390\/molecules29184338"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"344","DOI":"10.31925\/farmacia.2022.2.21","article-title":"Design, Synthesis, Biological Evaluation and Molecular Docking of Pyrrole-based Compounds as Antioxidant and MAO-B Inhibitory Agents","volume":"70","author":"Mattev","year":"2022","journal-title":"Farmacia"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kondeva-Burdina, M., Mateev, E., Angelov, B., Tzankova, V., and Georgieva, M. (2022). In Silico Evaluation and In Vitro Determination of Neuroprotective and MAO-B Inhibitory Effects of Pyrrole-Based Hydrazones: A Therapeutic Approach to Parkinson\u2019s Disease. Molecules, 27.","DOI":"10.3390\/molecules27238485"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Mateev, E., Karatchobanov, V., Dedja, M., Diamantakos, K., Mateeva, A., Muhammed, M.T., Irfan, A., Kondeva-Burdina, M., Valkova, I., and Georgieva, M. (2024). Novel Pyrrole Derivatives as Multi-Target Agents for the Treatment of Alzheimer\u2019s Disease: Microwave-Assisted Synthesis, In Silico Studies and Biological Evaluation. Pharmaceuticals, 17.","DOI":"10.3390\/ph17091171"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Georgieva, M., Sharkov, M., Mateev, E., Tzankova, D., Popov, G., Manov, V., Zlatkov, A., Simeonova, R., and Kondeva-Burdina, M. (2025). Classical Paal-Knorr Cyclization for Synthesis of Pyrrole-Based Aryl Hydrazones and In Vitro\/In Vivo Evaluation on Pharmacological Models of Parkinson\u2019s Disease. Molecules, 30.","DOI":"10.3390\/molecules30153154"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bmcl.2013.01.003","article-title":"Inhibition of Monoamine Oxidase by Phthalide Analogues","volume":"23","author":"Strydom","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.bmcl.2015.03.040","article-title":"The Synthesis and Evaluation of Sesamol and Benzodioxane Derivatives as Inhibitors of Monoamine Oxidase","volume":"25","author":"Engelbrecht","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.1016\/j.bmcl.2012.08.113","article-title":"Novel Sulfanylphthalimide Analogues as Highly Potent Inhibitors of Monoamine Oxidase B","volume":"22","author":"Petzer","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"104616","DOI":"10.1016\/j.bioorg.2020.104616","article-title":"Synthesis and in Vitro Study of Nitro- and Methoxy-2-Phenylbenzofurans as Human Monoamine Oxidase Inhibitors","volume":"107","author":"Delogu","year":"2021","journal-title":"Bioorg Chem"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/cmdc.201300533","article-title":"Insight into the Functional and Structural Properties of 3-Arylcoumarin as an Interesting Scaffold in Monoamine Oxidase\u2005B Inhibition","volume":"9","author":"Matos","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1039\/C7MD00311K","article-title":"MAO Inhibitory Activity of Bromo-2-Phenylbenzofurans: Synthesis, in Vitro Study, and Docking Calculations","volume":"8","author":"Delogu","year":"2017","journal-title":"Medchemcomm"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"107255","DOI":"10.1016\/j.bioorg.2024.107255","article-title":"Potent, Selective and Reversible HMAO-B Inhibition by Benzalphthalides: Synthesis, Enzymatic and Cellular Evaluations and Virtual Docking and Predictive Studies","volume":"146","author":"Barboza","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_88","first-page":"5479","article-title":"3-Coumaranone Derivatives as Inhibitors of Monoamine Oxidase","volume":"9","author":"Petzer","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cmdc.201500059","article-title":"Indanones as High-Potency Reversible Inhibitors of Monoamine Oxidase","volume":"10","author":"Mostert","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bioorg.2016.09.004","article-title":"2-Heteroarylidene-1-Indanone Derivatives as Inhibitors of Monoamine Oxidase","volume":"69","author":"Nel","year":"2016","journal-title":"Bioorg. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.bmcl.2019.02.030","article-title":"Discovery of Novel 2,3-Dihydro-1H-Inden-1-Amine Derivatives as Selective Monoamine Oxidase B Inhibitors","volume":"29","author":"Li","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/cmdc.201600122","article-title":"Synthesis, Biochemistry, and Computational Studies of Brominated Thienyl Chalcones: A New Class of Reversible","volume":"11","author":"Mathew","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1002\/slct.201901282","article-title":"Design, Synthesis and Docking Calculations of Prenylated Chalcones as Selective Monoamine Oxidase B Inhibitors with Antioxidant Activity","volume":"4","author":"Mellado","year":"2019","journal-title":"ChemistrySelect"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"127188","DOI":"10.1016\/j.bmcl.2020.127188","article-title":"Evaluation of Nitrocatechol Chalcone and Pyrazoline Derivatives as Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase","volume":"30","author":"Hitge","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"108837","DOI":"10.1016\/j.neuropharm.2021.108837","article-title":"Multitarget 2\u2032-Hydroxychalcones as Potential Drugs for the Treatment of Neurodegenerative Disorders and Their Comorbidities","volume":"201","author":"Kamecki","year":"2021","journal-title":"Neuropharmacol. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bioorg.2015.07.001","article-title":"Development of Fluorinated Methoxylated Chalcones as Selective Monoamine Oxidase-B Inhibitors: Synthesis, Biochemistry and Molecular Docking Studies","volume":"62","author":"Mathew","year":"2015","journal-title":"Bioorg. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/1570178612666150903213416","article-title":"Development of Fluorinated Thienylchalcones as Monoamine Oxidase-B Inhibitors: Design, Synthesis, Biological Evaluation and Molecular Dock-Ing Studies","volume":"12","author":"Mathew","year":"2015","journal-title":"Lett. Org. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/cbdv.201500367","article-title":"Potent and Selective Monoamine Oxidase-B Inhibitory Activity: Fluoro- vs. Trifluoromethyl-4-Hydroxylated Chalcones Derivatives","volume":"13","author":"Mathew","year":"2016","journal-title":"Chem. Biodivers."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/cmdc.201600497","article-title":"Monoamine Oxidase Inhibitory Activity: Methyl- versus Chlorochalcone Derivatives","volume":"11","author":"Mathew","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/acsmedchemlett.1c00238","article-title":"Promising Non-Cytotoxic Monosubstituted Chalcones to Target Monoamine Oxidase-B","volume":"12","author":"Iacovino","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"117990","DOI":"10.1016\/j.ejmech.2025.117990","article-title":"Design, Synthesis, and Biological Evaluation of Chalcone Derivatives as Selective Monoamine Oxidase-B Inhibitors with Potential Neuroprotective Effects","volume":"298","author":"Facchetti","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejmech.2012.11.006","article-title":"1,5-Diphenylpenta-2,4-Dien-1-Ones as Potent and Selective Monoamine Oxidase-B Inhibitors","volume":"59","author":"Desideri","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1016\/j.bmcl.2015.09.049","article-title":"Monoamine Oxidase Inhibitory Activities of Heterocyclic Chalcones","volume":"25","author":"Minders","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Rehuman, N.A., Oh, J.M., Abdelgawad, M.A., Beshr, E.A.M., Abourehab, M.A.S., Gambacorta, N., Nicolotti, O., Jat, R.K., Kim, H., and Mathew, B. (2022). Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors. Pharmaceuticals, 15.","DOI":"10.3390\/ph15091152"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"133545","DOI":"10.1016\/j.molstruc.2022.133545","article-title":"Development of Bromo- and Fluoro-Based \u03b1, \u03b2-Unsaturated Ketones as Highly Potent MAO-B Inhibitors for the Treatment of Parkinson\u2019s Disease","volume":"1266","author":"Abdelgawad","year":"2022","journal-title":"J. Mol. Struct."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1080\/14756366.2019.1653864","article-title":"Benzo[b]Tiophen-3-Ol Derivatives as Effective Inhibitors of Human Monoamine Oxidase: Design, Synthesis, and Biological Activity","volume":"34","author":"Guglielmi","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1016\/j.bmcl.2016.08.067","article-title":"2-Benzylidene-1-Indanone Derivatives as Inhibitors of Monoamine Oxidase","volume":"26","author":"Nel","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"\u0141a\u017cewska, D., Olejarz-maciej, A., Reiner, D., Kaleta, M., Latacz, G., Zygmunt, M., Doroz-P\u0142onka, A., Karcz, T., Frank, A., and Stark, H. (2020). Dual Target Ligands with 4-Tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103411"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1021\/jm501722s","article-title":"Novel Arylalkenylpropargylamines as Neuroprotective, Potent, and Selective Monoamine Oxidase B Inhibitors for the Treatment of Parkinson\u2019s Disease","volume":"58","author":"Huleatt","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/cmdc.201700589","article-title":"Synthesis, Biological Evaluation and Molecular Modeling Studies of Propargyl-Containing 2,4,6-Trisubstituted Pyrimidine Derivatives as Potential Anti-Parkinson Agents","volume":"13","author":"Kumar","year":"2018","journal-title":"ChemMedChem"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"128746","DOI":"10.1016\/j.bmcl.2022.128746","article-title":"The Evaluation of N-Propargylamine-2-Aminotetralin as an Inhibitor of Monoamine Oxidase","volume":"67","author":"Meiring","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1016\/j.bmcl.2012.10.070","article-title":"Sulfanylphthalonitrile Analogues as Selective and Potent Inhibitors of Monoamine Oxidase B","volume":"22","author":"Lourens","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"128917","DOI":"10.1016\/j.bmcl.2022.128917","article-title":"Synthesis and Human Monoamine Oxidase Inhibitory Activity of Novel C2-, C3- and C4-Substituted Phthalonitriles","volume":"74","author":"Ali","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1055\/s-0032-1323662","article-title":"The Inhibition of Monoamine Oxidase by 8-(2-Phenoxyethoxy)Caffeine Analogues","volume":"62","author":"Strydom","year":"2012","journal-title":"Arzneimittelforschung-Drug Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/jphp.12193","article-title":"Inhibition of Monoamine Oxidase by Selected Phenylalkylcaffeine Analogues","volume":"66","author":"Petzer","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1016\/j.bmc.2011.10.036","article-title":"Thio- and Aminocaffeine Analogues as Inhibitors of Human Monoamine Oxidase","volume":"19","author":"Booysen","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.bmcl.2011.12.094","article-title":"Design and Synthesis of 8-Substituted Benzamido-Phenylxanthine Derivatives as MAO-B Inhibitors","volume":"22","author":"Song","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.molstruc.2019.01.060","article-title":"Development of Piperic Acid-Based Monoamine Oxidase Inhibitors: Synthesis, Structural Characterization and Biological Evaluation","volume":"1182","author":"Chavarria","year":"2019","journal-title":"J. Mol. Struct."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"111770","DOI":"10.1016\/j.ejmech.2019.111770","article-title":"Design of Novel Monoamine Oxidase-B Inhibitors Based on Piperine Scaffold: Structure-Activity-Toxicity, Drug-Likeness and Efflux Transport Studies","volume":"185","author":"Chavarria","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"38855","DOI":"10.1007\/s11356-021-13320-y","article-title":"Piperazine-Substituted Chalcones: A New Class of MAO-B, AChE, and BACE-1 Inhibitors for the Treatment of Neurological Disorders","volume":"28","author":"Mathew","year":"2021","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bioorg.2018.01.020","article-title":"Synthesis, Biological Evaluation and Molecular Modeling Studies of Phenyl-\/Benzhydrylpiperazine Derivatives as Potential MAO Inhibitors","volume":"77","author":"Kumar","year":"2018","journal-title":"Bioorg. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cmdc.202000454","article-title":"7-Amidocoumarins as Multitarget Agents Against Neurodegenerative Diseases: Substitution Pattern Modulation","volume":"16","author":"Uriarte","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/cmdc.201500408","article-title":"3-Amidocoumarins as Potential Multifunctional Agents against Neurodegenerative Diseases","volume":"10","author":"Matos","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Vazquez-Rodriguez, S., Ferino, G., Cadoni, E., Matos, M.J., Quezada, E., Uriarte, E., Santana, L., Vilar, S., Tatonetti, N.P., and Y\u00e1\u00f1ez, M. (2011, January 1\u201330). Benzopyran-2-Ones as Attractive Scaffold for MAO Inhibitors: Synthesis, Biological Evaluation and Docking Studies. Proceedings of the 15th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-15), Online.","DOI":"10.3390\/ecsoc-15-00624"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"104685","DOI":"10.1016\/j.bioorg.2021.104685","article-title":"Design and Synthesis of Novel 3,4-Dihydrocoumarins as Potent and Selective Monoamine Oxidase-B Inhibitors with the Neuroprotection against Parkinson\u2019s Disease","volume":"109","author":"Liu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"117983","DOI":"10.1016\/j.ejmech.2025.117983","article-title":"Design, Synthesis, and Biological Activity of 2-Aroylbenzofuran-3-Ols and 2-Aroylbenzofuran Derivatives: A New Route Towards HMAO-B Inhibition","volume":"297","author":"Guglielmi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1021\/jm200716y","article-title":"Synthesis and Study of a Series of 3-Arylcoumarins as Potent and Selective Monoamine Oxidase B Inhibitors","volume":"54","author":"Matos","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejmech.2013.09.034","article-title":"Fine Molecular Tuning at Position 4 of 2H-Chromen-2-One Derivatives in the Search of Potent and Selective Monoamine Oxidase B Inhibitors","volume":"70","author":"Pisani","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/jm4000769","article-title":"Discovery, Biological Evaluation, and Structure-Activity and -Selectivity Relationships of 6\u2032-Substituted (E)-2-(Benzofuran-3(2H)-Ylidene)-N-Methylacetamides, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors","volume":"56","author":"Pisani","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"129984","DOI":"10.1016\/j.bmcl.2024.129984","article-title":"Design, Synthesis and Biological Evaluation of Novel Benzocoumarin Derivatives as Potent Inhibitors of MAO-B Activity","volume":"113","author":"Meletli","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejmech.2019.04.016","article-title":"Discovery of Coumarin Mannich Base Derivatives as Multifunctional Agents Against Monoamine Oxidase B and Neuroinflammation for the Treatment of Parkinson\u2019s Disease","volume":"173","author":"Tao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1016\/j.bmcl.2010.07.013","article-title":"New Halogenated 3-Phenylcoumarins as Potent and Selective MAO-B Inhibitors","volume":"20","author":"Matos","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/cmdc.201100538","article-title":"8-Substituted 3-Arylcoumarins as Potent and Selective MAO-B Inhibitors: Synthesis, Pharmacological Evaluation, and Docking Studies","volume":"7","author":"Matos","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"103986","DOI":"10.1016\/j.bioorg.2020.103986","article-title":"Discovery and Optimization of 3-Thiophenylcoumarins as Novel Agents Against Parkinson\u2019s Disease: Synthesis, In Vitro and In Vivo Studies","volume":"101","author":"Uriarte","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_135","first-page":"1702","article-title":"Design, Synthesis and Evaluation of Substituted Coumarin Derivatives as New Scaffold on Parkinson\u2019s Disease","volume":"9","author":"Siju","year":"2020","journal-title":"World J. Pharm. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s11030-019-09917-8","article-title":"Synthesis and Evaluation of Chromone Derivatives as Inhibitors of Monoamine Oxidase","volume":"23","author":"Mpitimpiti","year":"2019","journal-title":"Mol. Divers."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1021\/acs.jmedchem.6b00527","article-title":"Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors","volume":"59","author":"Reis","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bmcl.2010.11.128","article-title":"Chromone 3-Phenylcarboxamides as Potent and Selective MAO-B Inhibitors","volume":"21","author":"Gaspar","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1021\/jm2004267","article-title":"Chromone, a Privileged Scaffold for the Development of Monoamine Oxidase Inhibitors","volume":"54","author":"Gaspar","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1039\/C4CC08798D","article-title":"Discovery of Two New Classes of Potent Monoamine Oxidase-B Inhibitors by Tricky Chemistry","volume":"51","author":"Cagide","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11030-020-10143-w","article-title":"The Evaluation of 1-Tetralone and 4-Chromanone Derivatives as Inhibitors of Monoamine Oxidase","volume":"25","author":"Cloete","year":"2021","journal-title":"Mol. Divers."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejmech.2012.01.037","article-title":"Inhibition of Monoamine Oxidase by Selected C6-Substituted Chromone Derivatives","volume":"49","author":"Legoabe","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.bmcl.2010.03.081","article-title":"Chromone-2- and -3-Carboxylic Acids Inhibit Differently Monoamine Oxidases A and B","volume":"20","author":"Alcaro","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1016\/j.bmcl.2012.07.025","article-title":"Selected Chromone Derivatives as Inhibitors of Monoamine Oxidase","volume":"22","author":"Legoabe","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1016\/j.bmcl.2014.04.021","article-title":"\u03b1-Tetralone Derivatives as Inhibitors of Monoamine Oxidase","volume":"24","author":"Legoabe","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/cbdd.12508","article-title":"The Synthesis and Evaluation of C7-Substituted \u03b1-Tetralone Derivatives as Inhibitors of Monoamine Oxidase","volume":"86","author":"Legoabe","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1016\/j.bmcl.2013.08.071","article-title":"Inhibition of Monoamine Oxidase by 3,4-Dihydro-2(1H)-Quinolinone Derivatives","volume":"23","author":"Meiring","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_148","first-page":"170","article-title":"C6- and C7-Substituted 3,4-Dihydro-2(1H)-Quinolinones as Inhibitors of Monoamine Oxidase","volume":"67","author":"Meiring","year":"2017","journal-title":"Drug Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"117030","DOI":"10.1016\/j.bmc.2022.117030","article-title":"Isatoic Anhydrides as Novel Inhibitors of Monoamine Oxidase","volume":"73","author":"Hitge","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.14233\/ajchem.2015.18903","article-title":"Synthesis and Biological Evaluation of 1,2,3,4-Tetrahydroisoquinolines Derivatives as Monoamine Oxidase Inhibitors for Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases","volume":"27","author":"Guo","year":"2015","journal-title":"Asian J. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"26500","DOI":"10.1021\/acsomega.4c11530","article-title":"Investigating the Inhibitory Potential of Halogenated Quinoline Derivatives against MAO-A and MAO-B: Synthesis, Crystal Structure, Density Functional Theory, and Molecular Dynamics Simulations","volume":"10","author":"Oladipo","year":"2025","journal-title":"ACS Omega"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1016\/j.bmc.2015.04.021","article-title":"Synthesis and Evaluation of Quinazoline Amino Acid Derivatives as Mono Amine Oxidase (MAO) Inhibitors","volume":"23","author":"Khattab","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bioorg.2018.12.030","article-title":"The Monoamine Oxidase Inhibition Properties of C6-Mono- and N3\/C6-Disubstituted Derivatives of 4(3H)-Quinazolinone","volume":"85","author":"Qhobosheane","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.bmc.2018.09.032","article-title":"Synthesis and Evaluation of 2-Substituted 4(3H)-Quinazolinone Thioether Derivatives as Monoamine Oxidase Inhibitors","volume":"26","author":"Qhobosheane","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"117580","DOI":"10.1016\/j.ejmech.2025.117580","article-title":"2-(Phenylamino)-7,8-Dihydroquinazolin-5(6H)-One, a Promising Scaffold for MAO-B Inhibitors with Potential GSK3\u03b2 Targeting","volume":"291","author":"Salerno","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11030-019-09960-5","article-title":"The Monoamine Oxidase Inhibition Properties of C6- and N1-Substituted 3-Methyl-3,4-Dihydroquinazolin-2(1H)-One Derivatives","volume":"24","author":"Marais","year":"2020","journal-title":"Mol. Divers."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bmc.2017.11.036","article-title":"Synthesis and Evaluation of Biaryl Derivatives for Structural Characterization of Selective Monoamine Oxidase B Inhibitors Toward Parkinson\u2019s Disease Therapy","volume":"26","author":"Yeon","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1016\/j.bmc.2016.09.050","article-title":"Neuroprotective Effects of Benzyloxy Substituted Small Molecule Monoamine Oxidase B Inhibitors in Parkinson\u2019s Disease","volume":"24","author":"Wang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bmcl.2016.01.034","article-title":"Inhibition of Monoamine Oxidase by Benzoxathiolone Analogues","volume":"26","author":"Mostert","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ejmech.2016.11.016","article-title":"Benzyloxynitrostyrene Analogues\u2014A Novel Class of Selective and Highly Potent Inhibitors of Monoamine Oxidase B","volume":"125","author":"Petzer","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3109\/14756366.2016.1161621","article-title":"Synthesis of Some Novel 2-Substituted Benzothiazole Derivatives Containing Benzylamine Moiety as Monoamine Oxidase Inhibitory Agents","volume":"31","author":"Kaya","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1080\/14756366.2020.1784892","article-title":"Synthesis, in Vitro Enzyme Activity and Molecular Docking Studies of New Benzylamine-Sulfonamide Derivatives as Selective MAO-B Inhibitors","volume":"35","author":"Osmaniye","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.2147\/DDDT.S86225","article-title":"2-Acetylphenol Analogs as Potent Reversible Monoamine Oxidase Inhibitors","volume":"9","author":"Legoabe","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"958","DOI":"10.2174\/1570180811209050958","article-title":"Exploring Nitrostyrene as a Scaffold for a New Class a of Monoamine Oxidase Inhibitors","volume":"9","author":"Reis","year":"2012","journal-title":"Lett. Drug Des. Discov."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejmech.2017.04.055","article-title":"The Evaluation of 1,4-Benzoquinones as Inhibitors of Human Monoamine Oxidase","volume":"135","author":"Mostert","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bioorg.2016.11.004","article-title":"Symmetrical Aryl Linked Bis-Iminothiazolidinones as New Chemical Entities for the Inhibition of Monoamine Oxidases: Synthesis, in Vitro Biological Evaluation and Molecular Modelling Analysis","volume":"70","author":"Abbas","year":"2017","journal-title":"Bioorg. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/bkcs.11704","article-title":"Benzoxazoles as Selective Monoamine Oxidase B (MAO-B) Inhibitors","volume":"40","author":"Sawant","year":"2019","journal-title":"Bull. Korean Chem. Soc."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"116266","DOI":"10.1016\/j.ejmech.2024.116266","article-title":"Novel 6-Hydroxybenzothiazol-2-Carboxamides as Potent and Selective Monoamine Oxidase B Inhibitors Endowed with Neuroprotective Activity","volume":"269","author":"Gabr","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"126677","DOI":"10.1016\/j.bmcl.2019.126677","article-title":"1,3,4-Oxadiazol-2-Ylbenzenesulfonamides as Privileged Structures for the Inhibition of Monoamine Oxidase B","volume":"29","author":"Shetnev","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejmech.2015.12.026","article-title":"Drug Design, Synthesis, in Vitro and in Silico Evaluation of Selective Monoaminoxidase B Inhibitors Based on 3-Acetyl-2-Dichlorophenyl-5-Aryl-2,3-Dihydro-1,3,4-Oxadiazole Chemical Scaffold","volume":"108","author":"Distinto","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Presnukhina, S.I., Kotlyarova, V.D., Shetnev, A.A., Baykov, S.V., Turmanov, R., Appazov, N., Zhapparbergenov, R., Zhussupova, L., Togyzbayeva, N., and Cloete, S.J. (2024). Synthesis of 1,2,4-Oxadiazin-5(6H)-One Derivatives and Their Biological Investigation as Monoamine Oxidase Inhibitors. Molecules, 29.","DOI":"10.3390\/molecules29235550"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bmcl.2018.11.018","article-title":"Novel Monoamine Oxidase Inhibitors Based on the Privileged 2-Imidazoline Molecular Framework","volume":"29","author":"Shetnev","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/s00044-019-02388-4","article-title":"Novel Isoxazole Derivatives as Potential Antiparkinson Agents: Synthesis, Evaluation of Monoamine Oxidase Inhibitory Activity and Docking Studies","volume":"28","author":"Agrawal","year":"2019","journal-title":"Med. Chem. Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.compbiolchem.2019.01.012","article-title":"Synthesis, Monoamine Oxidase Inhibitory Activity and Computational Study of Novel Isoxazole Derivatives as Potential Antiparkinson Agents","volume":"79","author":"Agrawal","year":"2019","journal-title":"Comput. Biol. Chem."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"104563","DOI":"10.1016\/j.bioorg.2020.104563","article-title":"Investigation of Pyrazolo[1,5-a]Quinoxalin-4-Ones as Novel Monoamine Oxidase Inhibitors","volume":"108","author":"Panova","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1039\/C6MD00570E","article-title":"Pyrazolobenzothiazine-Based Carbothioamides as New Structural Leads for the Inhibition of Monoamine Oxidases: Design, Synthesis, in Vitro Bioevaluation and Molecular Docking Studies","volume":"8","author":"Abid","year":"2017","journal-title":"MedChemComm"},{"key":"ref_177","first-page":"510","article-title":"Design, Synthesis and HMAO Inhibitory Screening of Novel 2-Pyrazoline Analogues","volume":"20","author":"Ucar","year":"2017","journal-title":"Comb. Chem. High. Throughput Screen."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00044-022-02932-9","article-title":"Triphenylpyrazoline Ketone Chlorophenols as Potential Candidate Compounds against Parkinson\u2019s Disease: Design, Synthesis, and Biological Evaluation","volume":"31","author":"Cheng","year":"2022","journal-title":"Med. Chem. Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.bmc.2016.02.045","article-title":"Novel Tricyclic Pyrazolo[1,5-d][1,4]Benzoxazepin-5(6H)-One: Design, Synthesis, Model and Use as HMAO-B Inhibitors","volume":"24","author":"Chen","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"E87","DOI":"10.1002\/jhet.1072","article-title":"A Novel Series of 3,4-Disubstituted Dihydropyrazoles: Synthesis and Evaluation for MAO Enzyme Inhibition","volume":"50","author":"Cardia","year":"2013","journal-title":"J. Heterocycl. Chem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1021\/jm501690r","article-title":"New Frontiers in Selective Human MAO-B Inhibitors","volume":"58","author":"Carradori","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1016\/j.ejmech.2010.07.009","article-title":"Synthesis of New 3-Aryl-4,5-Dihydropyrazole-1-Carbothioamide Derivatives. An Investigation on Their Ability to Inhibit Monoamine Oxidase","volume":"45","author":"Maccioni","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.2174\/156802612805220057","article-title":"Discovery and Optimization of Pyrazoline Derivatives as Promising Monoamine Oxidase Inhibitors","volume":"12","author":"Secci","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mrc.2453","article-title":"Characterization of 2,5-Diaryl-1,3,4-Oxadiazolines by Multinuclear Magnetic Resonance and Density Functional Theory Calculations. Investigation on a Case of Very Remote Hammett Correlation","volume":"47","author":"Cerioni","year":"2009","journal-title":"Magn. Reson. Chem."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/j.bmcl.2006.04.026","article-title":"Synthesis, Molecular Modeling Studies, and Selective Inhibitory Activity against Monoamine Oxidase of N,N\u2032-Bis[2-Oxo-2H-Benzopyran]-3-Carboxamides","volume":"16","author":"Chimenti","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1021\/jm2002876","article-title":"3-Acetyl-2,5-Diaryl-2,3-Dihydro-1,3,4-Oxadiazoles: A New Scaffold for the Selective Inhibition of Monoamine Oxidase B","volume":"54","author":"MacCioni","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/14756366.2016.1247061","article-title":"Through Scaffold Modification to 3,5-Diaryl-4,5-Dihydroisoxazoles: New Potent and Selective Inhibitors of Monoamine Oxidase B","volume":"32","author":"Meleddu","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/acsmedchemlett.4c00354","article-title":"Optimizing Linezolid: Transforming It into a Selective MAO-B Inhibitor via a Toxicity-to-Activity Optimization Approach","volume":"16","author":"Dhangar","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1016\/j.bmc.2013.05.066","article-title":"Oxazolopyridines and Thiazolopyridines as Monoamine Oxidase B Inhibitors for the Treatment of Parkinson\u2019s Disease","volume":"21","author":"Park","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"114025","DOI":"10.1016\/j.ejmech.2021.114025","article-title":"Enhancing Monoamine Oxidase B Inhibitory Activity via Chiral Fluorination: Structure-Activity Relationship, Biological Evaluation, and Molecular Docking Study","volume":"228","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1039\/D0NJ04735J","article-title":"Synthesis of 2\u2032-(1,2,3-Triazoyl)-Acetophenones: Molecular Docking and Inhibition of: In Vitro Monoamine Oxidase Activity","volume":"45","author":"Costa","year":"2021","journal-title":"New J. Chem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"116566","DOI":"10.1016\/j.ejmech.2024.116566","article-title":"Discovery of Novel Benzimidazole Derivatives as Selective and Reversible Monoamine Oxidase B Inhibitors for Parkinson\u2019s Disease Treatment","volume":"274","author":"Lv","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s11030-023-10628-4","article-title":"Monoamine Oxidase Inhibition Properties of 2,1-Benzisoxazole Derivatives","volume":"28","author":"Shetnev","year":"2024","journal-title":"Mol. Divers"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Clark, D., Tuor, U.I., Thompson, R., Institoris, A., Kulynych, A., Zhang, X., Kinniburgh, D.W., Bari, F., Busija, D.W., and Barber, P.A. (2012). Protection against Recurrent Stroke with Resveratrol: Endothelial Protection. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047792"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.toxlet.2017.10.021","article-title":"Resveratrol Attenuates Oxidative Damage through Activating Mitophagy in an in Vitro Model of Alzheimer\u2019s Disease","volume":"282","author":"Wang","year":"2018","journal-title":"Toxicol. Lett."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exger.2018.09.019","article-title":"Resveratrol and Alzheimer\u2019s Disease. From Molecular Pathophysiology to Clinical Trials","volume":"113","author":"Drygalski","year":"2018","journal-title":"Exp. Gerontol."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Li, W., Yang, X., Song, Q., Cao, Z., Shi, Y., Deng, Y., and Zhang, L. (2020). Pyridoxine-Resveratrol Hybrids as Novel Inhibitors of MAO-B with Antioxidant and Neuroprotective Activities for the Treatment of Parkinson\u2019s Disease. Bioorg. Chem., 97.","DOI":"10.1016\/j.bioorg.2020.103707"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Enr\u00edquez, F., Costas-Lago, M.C., Besada, P., Alonso-Pena, M., Torres-Ter\u00e1n, I., Vi\u00f1a, D., Fontenla, J.\u00c1., Sturlese, M., Moro, S., and Quezada, E. (2020). Novel Coumarin-Pyridazine Hybrids as Selective MAO-B Inhibitors for the Parkinson\u2019s Disease Therapy. Bioorg. Chem., 104.","DOI":"10.1016\/j.bioorg.2020.104203"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2015.08.055","article-title":"Novel 2H-Chromen-2-One Derivatives of Resveratrol: Design, Synthesis, Modeling and Use as Human Monoamine Oxidase Inhibitors","volume":"103","author":"Ruan","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/cmdc.202000018","article-title":"Coumarin-Rasagiline Hybrids as Potent and Selective HMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents","volume":"15","author":"Matos","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Moya-Alvarado, G., Ya\u00f1ez, O., Morales, N., Gonz\u00e1lez-Gonz\u00e1lez, A., Areche, C., N\u00fa\u00f1ez, M.T., Fierro, A., and Garc\u00eda-Beltr\u00e1n, O. (2021). Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and in Silico Studies. Molecules, 26.","DOI":"10.3390\/molecules26092430"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/jphp.13264","article-title":"Design of Enamides as New Selective Monoamine Oxidase-B Inhibitors","volume":"72","author":"Kavully","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Osmaniye, D., Kurban, B., Sa\u011fl\u0131k, B.N., Levent, S., \u00d6zkay, Y., and Kaplanc\u0131kl\u0131, Z.A. (2021). Novel Thiosemicarbazone Derivatives: In Vitro and in Silico Evaluation as Potential Mao-b Inhibitors. Molecules, 26.","DOI":"10.3390\/molecules26216640"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1002\/slct.202002303","article-title":"Discovery of Novel Procaine-Imidazole Derivative as Inhibitor of Monoamine Oxidase-B for Potential Benefit in Parkinson\u2019s Disease","volume":"5","author":"Wu","year":"2020","journal-title":"ChemistrySelect"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"118123","DOI":"10.1016\/j.bmc.2025.118123","article-title":"New Phenylpiperazine-Thiazolidine-2,4-Dione Hybrids Targeting MAO Inhibition: Synthesis, Biological Evaluation, Kinetic Study and in Silico Insights","volume":"121","author":"Elgazar","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Oh, J.M., Zenni, Y.N., \u00d6zdemir, Z., Kumar, S., K\u0131l\u0131\u00e7, S., Akda\u011f, M., \u00d6z\u00e7elik, A.B., Kim, H., and Mathew, B. (2024). Inhibition of Monoamine Oxidases by Pyridazinobenzylpiperidine Derivatives. Molecules, 29.","DOI":"10.3390\/molecules29133097"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1568026619666190212122403","article-title":"In Silico Design, Synthesis of Hybrid Combinations: Quercetin Based MAO Inhibitors with Antioxidant Potential","volume":"19","author":"Dhiman","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.drudis.2019.05.003","article-title":"The Current Status of Pharmacotherapy for the Treatment of Parkinson\u2019s Disease: Transition from Single-Target to Multitarget Therapy","volume":"24","author":"Cheong","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Katsoulaki, E.-E., Dimopoulos, D., and Hadjipavlou-Litina, D. (2025). Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060831"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"126612","DOI":"10.1016\/j.bmcl.2019.08.016","article-title":"Rasagiline Derivatives Combined with Histamine H3 Receptor Properties","volume":"29","author":"Lutsenko","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1016\/j.bmcl.2018.10.048","article-title":"4-Tert-Pentylphenoxyalkyl Derivatives\u2014Histamine H3 Receptor Ligands and Monoamine Oxidase B Inhibitors","volume":"28","author":"Kaleta","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.bmc.2006.01.013","article-title":"Ether Derivatives of 3-Piperidinopropan-1-Ol as Non-Imidazole Histamine H3 Receptor Antagonists","volume":"14","author":"Ligneau","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnins.2018.00042","article-title":"The Histamine H3 Receptor Antagonist DL77 Ameliorates MK801-Induced Memory Deficits in Rats","volume":"12","author":"Eissa","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neuropharm.2015.10.023","article-title":"Anticonvulsant and Procognitive Properties of the Non-Imidazole Histamine H3 Receptor Antagonist DL77 in Male Adult Rats","volume":"106","author":"Sadek","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/cmdc.201600128","article-title":"Exploration of a Library of 3,4-(Methylenedioxy)Aniline-Derived Semicarbazones as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase: Design, Synthesis, and Evaluation","volume":"11","author":"Tripathi","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.ejmech.2017.10.050","article-title":"Design, Synthesis and Biochemical Evaluation of Novel Multi-Target Inhibitors as Potential Anti-Parkinson Agents","volume":"143","author":"Carradori","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/cmdc.201900277","article-title":"Experimental and Computational Evaluation of Piperonylic Acid Derived Hydrazones Bearing Isatin Moieties as Dual Inhibitors of Cholinesterases and Monoamine Oxidases","volume":"14","author":"Vishnu","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1039\/D2MD00042C","article-title":"Design, Synthesis and Biological Evaluation of Light-Driven on\u2013off Multitarget AChE and MAO-B Inhibitors","volume":"13","author":"Paolino","year":"2022","journal-title":"RSC Med. Chem."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"107066","DOI":"10.1016\/j.ejps.2025.107066","article-title":"Light-Mediated Activation\/Deactivation Control and in Vitro ADME-Tox Profiling of a Donepezil-like Dual AChE\/MAO-B Inhibitor","volume":"209","author":"Poggialini","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1080\/07391102.2020.1782266","article-title":"Development of Methylthiosemicarbazones as New Reversible Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson\u2019s Disease","volume":"39","author":"Mathew","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuroscience.2011.03.040","article-title":"Novel Molecular Targets of the Neuroprotective\/Neurorescue Multimodal Iron Chelating Drug M30 in the Mouse Brain","volume":"189","author":"Kupershmidt","year":"2011","journal-title":"Neuroscience"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1471-4159.2006.04258.x","article-title":"Therapeutic Targets and Potential of the Novel Brain-Permeable Multifunctional Iron Chelator\u2013Monoamine Oxidase Inhibitor Drug, M-30, for the Treatment of Alzheimer\u2019s Disease 1","volume":"100","author":"Amit","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S1353-8020(11)70047-5","article-title":"M30, a Brain Permeable Multi Target Neurorestorative Drug in Post Nigrostriatal Dopamine Neuron Lesion of Parkinsonism Animal Models","volume":"18","author":"Youdim","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12640-009-9070-9","article-title":"Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30","volume":"17","author":"Gal","year":"2010","journal-title":"Neurotox. Res."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bmc.2004.10.037","article-title":"Design, Synthesis, and Evaluation of Novel Bifunctional Iron-Chelators as Potential Agents for Neuroprotection in Alzheimer\u2019s, Parkinson\u2019s, and Other Neurodegenerative Diseases","volume":"13","author":"Zheng","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1471-4159.2005.03340.x","article-title":"Novel Multifunctional Neuroprotective Iron Chelator-monoamine Oxidase Inhibitor Drugs for Neurodegenerative Diseases: In Vitro Studies on Antioxidant Activity, Prevention of Lipid Peroxide Formation and Monoamine Oxidase Inhibition","volume":"95","author":"Zheng","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/cb900264w","article-title":"Site-Activated Chelators Targeting Acetylcholinesterase and Monoamine Oxidase for Alzheimer\u2019s Therapy","volume":"5","author":"Zheng","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"111681","DOI":"10.1016\/j.cbi.2025.111681","article-title":"N-Propargylpyrrolidine-Based Butyrylcholinesterase and Monoamine Oxidase Inhibitors","volume":"420","author":"Knez","year":"2025","journal-title":"Chem. Biol. Interact."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bioorg.2015.02.005","article-title":"The Adenosine Receptor Affinities and Monoamine Oxidase B Inhibitory Properties of Sulfanylphthalimide Analogues","volume":"59","author":"Petzer","year":"2015","journal-title":"Bioorg. Chem."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/cmdc.201900717","article-title":"Novel, Dual Target-Directed Annelated Xanthine Derivatives Acting on Adenosine Receptors and Monoamine Oxidase B","volume":"15","author":"Kuder","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cmdc.201402082","article-title":"8-Benzyltetrahydropyrazino[2,1-f]Purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases","volume":"9","author":"Brunschweiger","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1016\/j.bmc.2013.09.044","article-title":"1,3-Dialkyl-Substituted Tetrahydropyrimido[1,2-f]Purine-2,4-Diones as Multiple Target Drugs for the Potential Treatment of Neurodegenerative Diseases","volume":"21","author":"Koch","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bmc.2019.02.004","article-title":"Novel Multi-Target Directed Ligands Based on Annelated Xanthine Scaffold with Aromatic Substituents Acting on Adenosine Receptor and Monoamine Oxidase B. Synthesis, In Vitro and In Silico Studies","volume":"27","author":"Schabikowski","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0223-5234(03)00051-5","article-title":"Impact of the Aryl Substituent Kind and Distance from Pyrimido[2,1-f]Purindiones on the Adenosine Receptor Selectivity and Antagonistic Properties","volume":"38","author":"Schumacher","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"7258","DOI":"10.1016\/j.bmc.2006.06.052","article-title":"Synthesis and Biological Activity of Tricyclic Aryloimidazo-, Pyrimido-, and Diazepinopurinediones","volume":"14","author":"Lacher","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1016\/j.bmc.2007.07.051","article-title":"Phenylethyl-Substituted Pyrimido[2,1-f]Purinediones and Related Compounds: Structure-Activity Relationships as Adenosine A1 and A2A Receptor Ligands","volume":"15","author":"Schiedel","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1016\/j.ejmech.2011.05.023","article-title":"Synthesis and Biological Activity of Tricyclic Cycloalkylimidazo-, Pyrimido- and Diazepinopurinediones","volume":"46","author":"Yuzlenko","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fchem.2018.00206","article-title":"Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annelated Water-Soluble Xanthine Derivatives as Multi-Target Drugs with Potent Adenosine Receptor Antagonistic Activity","volume":"6","author":"Koch","year":"2018","journal-title":"Front. Chem."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Wang, X., Han, C., Xu, Y., Wu, K., Chen, S., Hu, M., Wang, L., Ye, Y., and Ye, F. (2017). Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists\/MAO-B Inhibitors for Parkinson\u2019s Disease. Molecules, 22.","DOI":"10.3390\/molecules22061010"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1021\/jm301686s","article-title":"Synthesis of (E)-8-(3-Chlorostyryl)Caffeine Analogues Leading to 9-Deazaxanthine Derivatives as Dual A2A Antagonists\/MAO-B Inhibitors","volume":"56","author":"Rivara","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1021\/jm400336x","article-title":"Dual Targeting of Adenosine A2A Receptors and Monoamine Oxidase B by 4H-3,1-Benzothiazin-4-Ones","volume":"56","author":"Schlenk","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1871524918666180426125714","article-title":"Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase","volume":"18","author":"Engelbrecht","year":"2018","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"107488","DOI":"10.1016\/j.bioorg.2024.107488","article-title":"Identification and Optimization of Nitrophenolic Analogues as Dopamine Metabolic Enzyme Inhibitors for the Treatment of Parkinson\u2019s Disease","volume":"148","author":"Zou","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"105130","DOI":"10.1016\/j.bioorg.2021.105130","article-title":"The Inhibition of Catechol O-Methyltransferase and Monoamine Oxidase by Tetralone and Indanone Derivatives Substituted with the Nitrocatechol Moiety","volume":"114","author":"Legoabe","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"114740","DOI":"10.1016\/j.ejmech.2022.114740","article-title":"Boosting Caffeic Acid Performance as Antioxidant and Monoamine Oxidase B\/Catechol-O-Methyltransferase Inhibitor","volume":"243","author":"Chavarria","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1039\/C6MD00228E","article-title":"Design, Synthesis, Biological Evaluation and Docking Studies of Sulfonyl Isatin Derivatives as Monoamine Oxidase and Caspase-3 Inhibitors","volume":"7","author":"Tavari","year":"2016","journal-title":"Medchemcomm"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/10\/1526\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:43:49Z","timestamp":1761122629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/10\/1526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":246,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ph18101526"],"URL":"https:\/\/doi.org\/10.3390\/ph18101526","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}